Apr. 3 at 6:35 PM
$ABEO,
IT MAKES NO SENSE. About a year ago you could have bought ABEO shares for about
$4.80. Today you can buy ABEO shares for around
$4.80. Which means in the last year there has been no value added for the
$150M in cash the company received for the sale of its PRV Voucher last June. No value for the FDA Approval of Zevaskyn. No value for the establishment of 5 Qaulified Treatment Centers. No value for securing a permanent HCPCS J-code and establishing coverage with major commercial payers, covering roughly 80% of insured lives, alongside Medicaid coverage in all 50 states. No value in having successfully treated new patients with Zevaskyn and no value in the
$191M in cash and investments they began 2026 with. So either ABEO was grossly over valued at
$4.80 a year ago, or it is grossly undervalued now at
$4.80. I choose the latter.
